Skip to content

PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE EFFECT OF GTX-024 ON MUSCLE WASTING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER ON FIRST LINE PLATINUM PLUS A TAXANE CHEMOTHERAPY

PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE EFFECT OF GTX-024 ON MUSCLE WASTING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER ON FIRST LINE PLATINUM PLUS A TAXANE CHEMOTHERAPY

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-100-11
Enrollment
20
Registered
2011-12-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

SUBJECTS WILL BE EVENLY RANDOMIZED TO PLACEBO OR GTX-024 PRIOR TO INITIATION OF FIRST LINE CHEMOTHERAPY. THE PRIMARY EFFICACY ANALYSIS WILL BE BASED ON TOTAL LBM AND PHYSICAL FUNCTION RESPONSES AS ASS

Sponsors

GTx, Inc.,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. GIVE VOLUNTARY, SIGNED INFORMED CONSENT IN ACCORDANCE WITH INSTITUTIONAL POLICIES 2. BE NON-OBESE AS DEFINED AS BODY MASS INDEX (BMI) ≤ 32 AND WEIGHT 300 POUNDS ( 6 MONTHS. 8. ECOG SCORE ≤ 1. 9. SERUM CREATININE ≤ 2.0 mg/dL. 10. MALES - AGE ≥ 30 YEARS. 11. FEMALES - AGE ≥ 30 YEARS AND CLINICALLY CONFIRMED POSTMENOPAUSAL. SUBJECTS MUST HAVE UNDERGONE THE ONSET OF SPONTANEOUS OR SURGICAL MENOPAUSE PRIOR TO THE START OF THIS STUDY. SPONTANEOUS MENOPAUSE IS DEFINED AS THE NATURAL CESSATION OF OVARIAN FUNCTION AS INDICATED BY BEING AMENORRHEIC AT LEAST 12 MONTHS.

Exclusion criteria

Exclusion criteria: 1. HAVE, IN THE JUDGMENT OF THE INVESTIGATOR, A CLINICALLY SIGNIFICANT CONCURRENT ILLNESS OR PSYCHOLOGICAL, FAMILIL, SOCIOLOGICAL, GEOGRAPHICAL OR OTHER CONCOMITANT CONDITION THAT WOLD NOT PERMIT ADEQUATE FOLLO UP AND COMPLIANCE WITH THE STUDY PROTOCOL. 2. HAVE ALT/GOT or AST/GPT ABOVE 1.5 TIMES THE UPPER LIMIT (ULN) WITHOUT EVIDENCE OF LIVER METASTASES AND ABOVE 5 TIMES THE ULN IN SUBJECTS WITH EVIDENCE OF LIVER METASTASES. 3. HAVE ALKALINE PHOSPHATASE GREATER THAN 3 TIMES ULN AND/OR TOTAL BILIRUBIN LEVELS ABOVE 2 mg/dL AT BASELINE. 4. HAVE BIOLOGIC AGENTS OR KINASE INHIBITORS AS PART OF THEIR FIRST LINE CHEMOTHERAPY REGIMEN INCLUDING, BUT NOT LIMITED TO BE BEVACIZUMAB (AVASTIN ®), GEFITINIB (IRESSA ®) AND ERLOTINIB (TARCEVA ®). 5. CARDIOVASCULAR: UNCONTROLLED HYPERTENSION, CONGESTIVE HEART FAILURE OR ANGINA. 6. PULMONARY: STAGE 4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). 7. POSITIVE SCREEN FOR HEPATITIS B CONSISTING OF HBsAg (HEPATITIS B SURFACE ANTIGEN), UNLESS SUBJECT WAS DIAGNOSED > 10 YEARS PRIOR TO ENROLLMENT AND NO EVIDENCE OF ACTIVE LIVER DISEASE.

Countries

United States

Contacts

Public ContactLEOPOLDO VALDEZ

ACTIVA CRO PERU SOCIEDAD ANONIMA CERRADA

lvaldez@activa-cro.com6121407 - 6121411

Outcome results

None listed

Source: REPEC (via WHO ICTRP)